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Prasugrel is a new-generation thienopyridine that exhibits
a more potent, less variable, and faster platelet blockade of
the purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) -
adenosine diphosphate (ADP) receptor compared with
clopidogrel, as demonstrated by the results of early phase
studies performed in healthy volunteers and stable coronary
artery disease patients (1). Following these encouraging
results, the TRITON–TIMI 38 (Trial to Assess Improve-
ment in Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel–Thrombolysis In Myocardial
Infarction 38) trial (2) conﬁrmed the beneﬁt of prasugrel
over clopidogrel in patients with acute coronary syndromes
(ACS) undergoing percutaneous coronary intervention
(PCI). In this study, a near-20% risk reduction was obtained
regarding the ischemic endpoint, thanks to improved
platelet reactivity (PR) inhibition. On the other hand,
a signiﬁcant increase in bleedings was observed, suggesting
a link between excessive P2Y12-ADP receptor blockade
and post-PCI bleedings.See page 513Following these clinical results, prasugrel obtained a 1b
level of recommendation in guidelines for ACS. In the
European Society of Cardiology guidelines, prasugrel over-
came clopidogrel, which was downgraded to 1c and con-
sidered as a second-line agent in ACS patients receiving
PCI (3).
In early clinical studies in ST-segment elevation
myocardial infarction patients, Alexopoulos et al. (4)
observed that despite its quicker onset of action, prasugrel
was associated with, similar to clopidogrel, a longer delay of
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conﬁrmed that prasugrel was associated with an inter-
individual variability, although it was reduced com-
pared with clopidogrel (5). Accordingly, some patients are
considered as having high on-treatment PR under prasugrel.
On the other hand, some patients exhibited low on-
treatment PR. Of importance, accumulating evidence
suggests that excessive PR inhibition is associated with
bleeding complications. Accordingly, preliminary ﬁndings
suggested that the inter-individual variability in prasugrel
responsiveness may be involved in ischemic and bleeding
events. Indeed, a recent prospective and observational study
of prasugrel in “real-world” ACS patients undergoing PCI
suggested that PR following the loading dose was predictive
of both ischemic and bleedings events at 1-year follow-up
(6). Gurbel’s hypothesis of a therapeutic window of PR to
prevent ischemic and bleeding events may, therefore, be
valid for prasugrel (7). Identifying the factors associated with
variability in prasugrel responsiveness is thus of potential
clinical interest.
In the era of clopidogrel, several factors were shown
to affect P2Y12-ADP receptor blockade, although it was
not completely elucidated. Extrinsic factors mainly include
drug–drug interactions affecting the biotransformation
of clopidogrel into its active metabolite, noncompliance
with clopidogrel therapy, and underdosing or inappropriate
dosing of clopidogrel, and intrinsic factors include diabetes
mellitus; polymorphisms of the P2Y12 receptor gene, leading
to an increased number of P2Y12 receptors; and poly-
morphisms of the gene that encodes cytochrome P450 3A
(CYP3A) (8).
On the contrary, there are very few data available
regarding the factors associated with prasugrel variability.
This is related to the facts that prasugrel is a novel anti-
platelet agent and that it is associated with a reduced vari-
ability compared with clopidogrel, thus requiring a larger
cohort of patients to identify its determinants.
Interestingly, a recent study by Frelinger et al. (9) sug-
gested that among all intrinsic and extrinsic factors, baseline
platelet activity may be the main factor in on-prasugrel
variability.
Guthikonda et al. (10) previously demonstrated that the
proportion of reticulated platelets (RPs) was a key deter-
minant of PR in stable coronary artery disease patients
during clopidogrel therapy. In line with these ﬁndings,
Perl et al. (11), in this issue of the Journal, aimed to
investigate, in a prospective study, the potential role of
RPs in the inter-individual variability in PR under pra-
sugrel (11).
RPs are newly formed platelets with high granule
content and a residual amount of mRNA. They appear to
be the youngest circulating platelets in animals (12). It
was demonstrated that thiazole orange–positive platelets
observed in dogs were <24 h old and reﬂected an increased
platelet turnover (13). Interestingly, these newly formed
platelets may have a higher thrombotic potential. Increased
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519RP percentages have been found in various clinical condi-
tions, including thrombocytopenia-associated and -dissem-
inated intravascular coagulation and, more recently, arterial
thrombosis including stent thrombosis and ACS (14,15). In
addition, RPs are independent predictors of cardiovascular
death at 12-month follow-up in patients with ACS treated
with PCI (16). Level of RP could therefore be a marker of
risk or a risk factor for ischemic events. It could act through
a modulation of the response to antiplatelet therapy, as
observed with clopidogrel.
In the present study, Perl et al. (11) observed that in
STEMI patients, on-prasugrel PR was variable both in the
acute and chronic phases, with some patients with extreme
PR levels. In this study PR was stable over time. The authors
also conﬁrmed that despite the use of prasugrel, there was
a correlation between the proportion of RP and on-prasugrel
PR. In fact, patients in the upper tertiles of RP exhibited
higher PR. These ﬁndings conﬁrmed that RP could be
a good marker to predict nonresponse to prasugrel and the
risk of thrombosis.
This study has several strengths. First, it is focused on
a very clinically signiﬁcant population: STEMI patients
treated with PCI in which PR inhibition is critical.
Second, 2 well-validated platelet assays were used to
measure PR. Third, unlike most studies, the authors
measured PR and RP proportion both in the acute and
chronic phases of antiplatelet therapy. However, there are
some limitations to the present ﬁndings. In particular, the
small number of patients does not allow for multivariable
analysis, and the clinical implications of the ﬁndings were
not assessed.
Overall, the results of the present study give an inter-
esting insight into the mechanism of platelet activity in
STEMI patients in the era of potent P2Y12-ADP receptor
antagonists. If conﬁrmed, this could have a clinical impact
in the selection, dose, or frequency of prasugrel use in
STEMI patients. To achieve a more complete platelet-
activity blockade, twice-daily thienopyridine uptake may
have the ability to act more deeply on these young platelets
by increasing platelets’ exposition to active metabolites.
With age, these young, turbulent platelets will hopefully
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